ZIOPHARM Oncology Inc:
The company is focused on the development of two platform technologies designed to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of multiple cancer types: (1) Controlled IL-12 for turning cold tumors hot and (2) Sleeping Beauty (SB) a non-viral approach to genetically modifying cells with significantly shortened manufacturing and lower COGS. Plan to submit an IND to evaluate SB-modified TCRs targeting neoantigens to treat solid tumors in Q4 2018 followed by enrollment of patients at the NCI beginning in 2019. Currently enrolling patients in a phase 1 trials of Ad-RTS-hIL-12 as monotherapy and in combination with OPDIVO for the treatment of rGBM.
1 1st Ave
Charlestown, MA 02129
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Stock Market Data
Market Data copyright © 2017 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by